SCHEDULE: Samsara BioCapital Reduces NKARTA Stake Below 5%

Samsara BioCapital and its affiliates have reduced their beneficial ownership in NKARTA, INC. to 4.9%, falling below the 5% threshold.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (Reporting Persons) filed Amendment No. 3 to their Schedule 13D.
• The Reporting Persons ceased to be beneficial owners of more than 5% of NKARTA, INC.'s common stock on November 20, 2025.
• Samsara BioCapital, L.P. sold a total of 260,369 shares of common stock in open market transactions between November 17, 2025, and November 20, 2025.
• Sales occurred at weighted-average prices ranging from $1.73 to $1.82 per share.
• The shares sold were held for limited partners who had redeemed their interests in Samsara LP, with Samsara GP and Dr. Akkaraju having no economic interest in these specific shares.
• As of the filing, the Reporting Persons beneficially own 3,507,666 shares, representing 4.9% of NKARTA, INC.'s common stock.
• The percentage is based on 71,029,512 shares outstanding as of November 5, 2025.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as a significant institutional investor has reduced its stake below the 5% threshold, which can be perceived as a lack of confidence or a strategic divestment, even if attributed to limited partner redemptions.

Negatives

• A significant institutional investor, Samsara BioCapital, has reduced its stake in NKARTA, INC. below the 5% beneficial ownership threshold.
• The sales occurred at prices ranging from $1.71 to $1.89 per share, indicating a specific price range at which the investor exited a portion of their position.

Risks

• The reduction in a significant institutional investor's stake could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.
• Increased selling pressure on the stock due to the disposition of a large block of shares.

Future Outlook

NA

Industry Context

The reduction of a significant stake by a biotech-focused investor like Samsara BioCapital in a biotechnology company like NKARTA could reflect broader trends in the biotech investment landscape, such as portfolio rebalancing or a shift in focus towards other opportunities, though the filing attributes the sales to limited partner redemptions.

Stakeholder Impact

• Shareholders: May experience increased selling pressure and a potential negative perception of the stock due to a large investor reducing their stake.
• Limited Partners of Samsara LP: Those who redeemed their interests received proceeds from the sale of NKARTA shares.

Key Dates

Recommendation

The reduction of a significant institutional stake below the 5% threshold by Samsara BioCapital, even if attributed to limited partner redemptions, typically signals a lack of conviction or a strategic exit from a portion of the investment. This action can lead to negative market sentiment and increased selling pressure on the stock, making it prudent for investors to consider selling or reducing their position.

Keywords

NKARTA INC, NKARTA, Samsara BioCapital, Schedule 13D/A, Beneficial Ownership, Stock Sales, Institutional Investor, Biotechnology, Healthcare